CU-CPT 4a is a selective agonist of the GPR35 receptor, making it a valuable tool in pharmacological research focused on inflammatory and metabolic diseases. It is widely used in studies exploring the role of GPR35 in immune regulation, particularly in models of colitis and other gastrointestinal inflammatory conditions. Its high selectivity allows researchers to activate GPR35 signaling pathways without significant off-target effects, facilitating clear interpretation of receptor function. Additionally, CU-CPT 4a has been employed in diabetes and obesity-related research due to GPR35’s involvement in insulin secretion and glucose homeostasis. The compound is primarily used in vitro and in animal models to probe receptor mechanisms and assess therapeutic potential.